Drug intelligence / Profile preview

AXP1044

Development stage: Preclinical
Lead developer: Xiamen Innovax Biotech
Modality: Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

AXP1044 is a preclinical-stage recombinant chimeric multi-epitope vaccine being developed by Sino-Innovax Biotech for the prevention of human papillomavirus (HPV) infections and related diseases, including cervical cancer, penile cancer, and genital warts. Utilizing structural vaccinology and a proprietary chimeric multi-epitope antigen design, AXP1044 is engineered to induce broad immunity against multiple HPV genotypes. This next-generation vaccine aims to provide expanded protection compared to traditional HPV vaccines by displaying multiple protective epitopes on a single chimeric antigen, thereby simplifying manufacturing and potentially reducing production costs.

Other names: Third-Generation HPV Vaccine第三代HPV疫苗

Beyond the preview

Go deeper on AXP1044.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AXP1044.

Explore the full profile